Legal & General Group Plc lessened its holdings in The Medicines Company (NASDAQ:MDCO) by 6.6% in the third quarter, according to its most recent filing with the SEC. The institutional investor owned 129,526 shares of the company’s stock after selling 9,196 shares during the period. Legal & General Group Plc owned 0.18% of The Medicines worth $4,794,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. FMR LLC boosted its holdings in shares of The Medicines by 1.1% during the 2nd quarter. FMR LLC now owns 10,825,038 shares of the company’s stock valued at $411,460,000 after purchasing an additional 117,982 shares during the last quarter. Iridian Asset Management LLC CT boosted its holdings in shares of The Medicines by 21.7% during the 2nd quarter. Iridian Asset Management LLC CT now owns 3,677,746 shares of the company’s stock valued at $139,791,000 after purchasing an additional 655,065 shares during the last quarter. State Street Corp boosted its holdings in shares of The Medicines by 9.0% during the 2nd quarter. State Street Corp now owns 2,220,199 shares of the company’s stock valued at $84,391,000 after purchasing an additional 183,086 shares during the last quarter. Westfield Capital Management Co. LP boosted its holdings in shares of The Medicines by 947.1% during the 2nd quarter. Westfield Capital Management Co. LP now owns 2,031,359 shares of the company’s stock valued at $77,212,000 after purchasing an additional 1,837,359 shares during the last quarter. Finally, Franklin Resources Inc. boosted its holdings in shares of The Medicines by 24.1% during the 2nd quarter. Franklin Resources Inc. now owns 1,765,169 shares of the company’s stock valued at $67,093,000 after purchasing an additional 343,160 shares during the last quarter.

The Medicines Company (NASDAQ:MDCO) opened at $26.32 on Tuesday. The company has a current ratio of 2.31, a quick ratio of 1.79 and a debt-to-equity ratio of 3.42. The Medicines Company has a 1-year low of $25.40 and a 1-year high of $55.95.

The Medicines (NASDAQ:MDCO) last announced its quarterly earnings results on Wednesday, October 25th. The company reported ($0.42) EPS for the quarter, beating the Zacks’ consensus estimate of ($1.37) by $0.95. The Medicines had a negative net margin of 767.94% and a negative return on equity of 174.68%. The firm had revenue of $16.87 million during the quarter, compared to the consensus estimate of $26.06 million. During the same quarter last year, the firm earned ($0.64) EPS. The firm’s revenue for the quarter was down 55.1% compared to the same quarter last year. sell-side analysts expect that The Medicines Company will post -8.86 EPS for the current fiscal year.

In other The Medicines news, insider Fredric N. Eshelman purchased 200,000 shares of the stock in a transaction that occurred on Friday, December 8th. The stock was purchased at an average price of $26.56 per share, with a total value of $5,312,000.00. Following the acquisition, the insider now owns 1,028,383 shares in the company, valued at $27,313,852.48. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Alexander J. Denner purchased 170,000 shares of the stock in a transaction that occurred on Wednesday, November 29th. The stock was acquired at an average cost of $30.03 per share, with a total value of $5,105,100.00. Following the acquisition, the director now owns 6,663 shares in the company, valued at approximately $200,089.89. The disclosure for this purchase can be found here. 8.22% of the stock is currently owned by company insiders.

Several research analysts have commented on the stock. ValuEngine raised shares of The Medicines from a “sell” rating to a “hold” rating in a report on Friday, December 1st. Chardan Capital reissued a “buy” rating and set a $85.00 price objective on shares of The Medicines in a report on Wednesday, September 20th. Guggenheim assumed coverage on shares of The Medicines in a report on Monday, October 23rd. They set a “buy” rating and a $45.00 price objective for the company. Citigroup raised shares of The Medicines from a “sell” rating to an “outperform” rating in a report on Thursday, November 30th. Finally, Jefferies Group reaffirmed a “buy” rating and issued a $54.00 price target on shares of The Medicines in a report on Thursday, October 26th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $53.67.

TRADEMARK VIOLATION WARNING: “Legal & General Group Plc Has $4.79 Million Holdings in The Medicines Company (MDCO)” was first posted by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright legislation. The correct version of this news story can be read at https://www.watchlistnews.com/legal-general-group-plc-has-4-79-million-holdings-in-the-medicines-company-mdco/1772328.html.

About The Medicines

The Medicines Company is a global biopharmaceutical company. The Company is focused on advancing the treatment of acute and intensive care patients through the delivery of medicines to the hospital marketplace around the world. It markets Angiomax (bivalirudin), Ionsys (fentanyl iontophoretic transdermal system), Minocin (minocycline) for injection and Orbactiv (oritavancin).

Institutional Ownership by Quarter for The Medicines (NASDAQ:MDCO)

Receive News & Ratings for The Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Medicines and related companies with MarketBeat.com's FREE daily email newsletter.